Commercial Strategies

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

The France-based giant inks a transaction potentially worth around $1.9bn to get hold of Dren Bio’s autoimmune disease treatment DR-0201.

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer

ModMed unveiled its AI-powered ambient listening and clinical documentation software for orthopedic clinics at AAOS, ahead of its planned late-summer release. The health care software provider aims to create “the AI-powered practice” for specialty clinics to reduce clinicians' administrative burden and streamline clinical workflows.

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.

CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.

In a video interview, Wockhardt chairman Habil Khorakiwala talks about global commercial and manufacturing plans for superbug-busting novel antibiotics and developments such as proposed US tariffs and the Windsor framework that could impact its markets.

Innogen is hoping the approval of its once-weekly GLP-1 drug Diabegone will allow it to chip away at Ozempic’s dominance in the Chinese diabetes market.